Redcare Pharmacy: A Compelling Investment After Steep Decline?

A significant vote of confidence has been placed in Redcare Pharmacy, not through words, but through a substantial financial commitment. Björn Söder, the company’s Chairman of the Supervisory Board, recently acquired company shares worth nearly €128,000. This move comes at a pivotal moment for the online pharmacy, whose stock has lost more than half its value since the start of the year and is currently trading at a 52-week low. This gesture from the top leadership raises a critical question: is this a signal that the equity is poised for a rebound?

Financial Health Defies Share Price Performance

Despite the stock’s dramatic collapse from its December 2024 peak of €160 to approximately €60—a drop exceeding 60%—the underlying business tells a different story. The operational metrics for the third quarter of 2025 were robust.

Revenue climbed by 25.2% to reach €719.2 million. For the first nine months of the year, sales advanced by 26.6% to €2.15 billion. Key performance indicators underscore this strength:
* The active customer base grew to 13.7 million, an annual increase of 1.8 million.
* Customer loyalty remains exceptionally high, evidenced by a 90% reorder rate.
* The average shopping cart value rose by 8.5% to €67.10.
* The company maintains a remarkably low returns rate of just 0.7%.

Profitability is also on an upward trajectory. The adjusted EBITDA for Q3 hit €17 million, representing a 50% surge compared to the previous year. The resulting EBITDA margin of 2.4% aligns with the full-year forecast range of 2% to 2.5%.

The Prescription Business Fuels Growth

A major growth engine for Redcare is its German prescription (Rx) segment. Revenue from prescription medications skyrocketed by 122% in the first nine months of the year. The company is capitalizing on the widespread adoption of the e-prescription and the increasing consumer acceptance of digital pharmacy services.

Beyond prescriptions, the over-the-counter (Non-Rx) segment continues to deliver solid, double-digit growth of 18%, demonstrating that Redcare’s success is not reliant on a single market niche but is built on a diversified business model.

Should investors sell immediately? Or is it worth buying Redcare Pharmacy?

Strategic Hire Points to Ambitious Goals

Adding to the positive developments, Redcare has secured a new Chief Financial Officer with a prestigious background. Effective December 1, 2025, Hendrik Krampe will take the helm of the finance department. Krampe joins from Amazon, where he spent eight years leading the finance division for the European marketplace business, following a tenure at eBay. His expertise lies in scaling digital business models and enhancing their profitability.

This appointment signals the company’s intent to navigate its next growth phase while sharpening its focus on earnings. The long-term ambition is to achieve an EBITDA margin exceeding 8%.

A Strong Balance Sheet Provides a Foundation

The company’s financial position remains solid. At the end of the third quarter, Redcare held €266 million in liquid assets, an increase of €88 million since the beginning of the year. The twelve-month operational cash flow (excluding the German Rx business) stands at over €100 million and continues to show a positive trend. This capital-light model allows the company to fund expansion and ongoing investments in logistics and automation without straining its balance sheet.

Insider Purchase Amid Market Pessimism

The context of Chairman Björn Söder’s share acquisition on November 11, 2025, is what makes it particularly noteworthy. His purchase of 2,000 shares at €63.98 each via Xetra occurred when investor sentiment was at a low ebb. Transactions of this nature by corporate insiders are rarely coincidental; they typically indicate that leadership considers the stock undervalued and has conviction in its long-term recovery prospects.

This internal confidence is mirrored by external analysis. Market experts have set one-year price targets for Redcare Pharmacy between €146 and €157. This suggests a potential upside of over 140% from current levels. The majority of the 25 analysts covering the stock maintain positive recommendations, despite recent volatility.

The convergence of a deeply discounted share price, strong operational results, a strategic new executive, and a clear demonstration of faith from its leadership presents a compelling case for investors willing to look beyond short-term market movements. The path to recovery will ultimately depend on the company’s continued execution against its profitability targets and the market’s subsequent recognition of that success.